Dynamics of antibody response to CoronaVac vaccine
Dynamics of antibody response to CoronaVac vaccine
复制标题
DOI：
10.1002/jmv.27604
复制
发表时间：
2022-01-28
影响因子：
12.7
通讯作者：
Monteiro de Andrade, Luiz Odorico
中科院分区：
文献类型：
--
作者：
Gambim Fonseca, Marcela Helena;Goebel de Souza, Tamiris de Fatima;Monteiro de Andrade, Luiz Odorico
CoronaVac是巴西批准用于医疗保健工作者（HCW）的第一种疫苗。然而，关于它的信息有限，几乎没有关于疫苗接种后抗体持久性的长期证据。本研究评价了1237名HCW在第一剂（1D）、第二剂（2D）和接种CoronaVac后6个月（6 mA 2D）对SARS-CoV-2的抗体应答。在1D时血清阳性率为88%，在2D时增加至99.8%，但在6 mA 2D时降低至97.9%，这也在分析的抗体水平下观察到。有趣的是，女性的水平高于男性，我们发现与先前的SARS-CoV-2感染呈正相关。有合并症的参与者水平较低，表明需要监测潜在的加强剂量。我们的研究结果表明，CoronaVac诱导了一种强大的抗体应答，这种应答随着时间的推移而显著减弱。需要进一步的纵向研究，以确定抗体是否会下降或在较低水平的平台。
CoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long-term evidence on post-vaccination antibody persistence. This study evaluated the antibody response to SARS-CoV-2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months postvaccination (6mA2D) with CoronaVac. The seropositivity was 88% at 1D, increasing to 99.8% at 2D, but decreasing to 97.9% at 6mA2D, which was also observed at the analyzed antibody levels. Interestingly, the levels in females were higher than males, and we found a positive correlation with previous SARS-CoV-2 infection. Participants with comorbidities had lower levels suggesting the need to monitor for a potential booster dose. Our findings suggest that CoronaVac induced a robust antibody response that wanes significantly over time. Further longitudinal studies are needed to identify whether the antibodies will decline or plateau at a lower level.